The Clinical Trials Abundance blog

Market shaping and trial design belong together

Two birds, one trial

Jul 14 • Witold Więcek

16

8

4

June 2026

Why were Covid vaccine trials so fast?

The timeline to develop coronavirus vaccines blew many predictions out of the water.

Jun 26 • Saloni Dattani

85

4

22

The new HHS trial reforms are more ambitious than they look

A Deeper Dive into Operation TrialBlazer

Jun 23 • Adam Kroetsch

11

4

The US moves to reclaim the therapeutic pipeline

A welcome move from the FDA and HHS

Jun 22 • Ruxandra Teslo

13

5

1

Manufacturing requirements are killing cell and gene therapy

Some of the most promising drugs are bottlenecked by a "boring" but incredibly important problem

Jun 10 • Ruxandra Teslo and Amol Punjabi

27

1

2

Clinical trial innovations don't scale. Here's why, and how to fix it.

A Policy Agenda for Efficient, Abundant Clinical Trials

Published on Policy and Practice • Jun 8

Who Owns the FDA's Thinking?

A law firm says that FDA’s rejection letters reveal too much. That may be exactly why the public needs them.

Published on Policy and Practice • Jun 1

May 2026

FDA’s Real-Time Clinical Trials Pilot Could Transform Drug Development

The approach is promising. The challenge is scaling it up.

May 11 • Adam Kroetsch

31

6

8

April 2026

How to speed up clinical trials

Why is drug testing so slow and inefficient, and how can we fix it?

Published on The Works in Progress Newsletter • Apr 22

56:13

Clinical Trials Were Not Always This Complicated

How trials got so bureaucratic, and how some leaders pushed back

Apr 8 • Adam Kroetsch

45

4

11

March 2026

FDA Bayesian trials guidance is good, but will we make a good use of it?

How can regulators apply their own guidance?

Mar 30 • Witold Więcek

18

7

Perhaps you, too, could work on Clinical Trial Abundance!

1Day Sooner are hiring a policy lead for their new Clinical Trial Abundance program.

Mar 13 • Saloni Dattani

9

5